News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
394,028 Results
Type
Article (26340)
Company Profile (60)
Press Release (367626)
Multimedia
Podcasts (35)
Webinars (7)
Section
Business (104374)
Career Advice (456)
Deals (16887)
Drug Delivery (53)
Drug Development (47735)
Employer Resources (47)
FDA (12348)
Job Trends (8485)
News (186340)
Policy (19523)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (1)
Academia (1758)
Accelerated approval (14)
Adcomms (10)
Allergies (114)
Alliances (26824)
ALS (97)
Alzheimer's disease (978)
Antibody-drug conjugate (ADC) (163)
Approvals (12684)
Artificial intelligence (313)
Autoimmune disease (94)
Automation (8)
Bankruptcy (142)
Best Places to Work (6891)
BIOSECURE Act (5)
Biosimilars (73)
Biotechnology (40)
Bladder cancer (124)
Brain cancer (37)
Breast cancer (420)
Cancer (3091)
Cardiovascular disease (266)
Career advice (417)
Career pathing (16)
CAR-T (134)
CDC (26)
Celiac Disease (2)
Cell therapy (366)
Cervical cancer (26)
Clinical research (42973)
Collaboration (864)
Compensation (275)
Complete response letters (16)
COVID-19 (1555)
CRISPR (35)
C-suite (505)
Cystic fibrosis (59)
Data (4264)
Decentralized trials (2)
Denatured (21)
Depression (93)
Diabetes (318)
Diagnostics (3721)
Digital health (31)
Diversity (7)
Diversity, equity & inclusion (13)
Drug discovery (95)
Drug pricing (91)
Drug shortages (22)
Duchenne muscular dystrophy (126)
Earnings (38651)
Editorial (29)
Employer branding (6)
Employer resources (47)
Events (54221)
Executive appointments (593)
FDA (14644)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (6)
Frontotemporal dementia (10)
Funding (762)
Gene editing (75)
Generative AI (22)
Gene therapy (261)
GLP-1 (544)
Government (3143)
Grass and pollen (4)
Guidances (229)
Healthcare (12212)
HIV (39)
Huntington's disease (20)
IgA nephropathy (50)
Immunology and inflammation (84)
Immuno-oncology (28)
Indications (73)
Infectious disease (1691)
Inflammatory bowel disease (111)
Inflation Reduction Act (7)
Influenza (54)
Intellectual property (120)
Interviews (40)
IPO (7072)
IRA (23)
Job creations (1846)
Job search strategy (382)
JPM (19)
Kidney cancer (11)
Labor market (36)
Layoffs (195)
Leadership (9)
Legal (3646)
Liver cancer (66)
Longevity (7)
Lung cancer (488)
Lymphoma (253)
Machine learning (16)
Management (17)
Manufacturing (291)
MASH (107)
Medical device (13309)
Medtech (13355)
Mergers & acquisitions (10328)
Metabolic disorders (761)
Multiple sclerosis (100)
NASH (11)
Neurodegenerative disease (163)
Neuropsychiatric disorders (42)
Neuroscience (1702)
NextGen: Class of 2026 (3933)
Non-profit (2838)
Now hiring (35)
Obesity (316)
Opinion (96)
Ovarian cancer (120)
Pain (141)
Pancreatic cancer (142)
Parkinson's disease (164)
Partnered (17)
Patents (228)
Patient recruitment (360)
Peanut (43)
People (35678)
Pharmaceutical (15)
Pharmacy benefit managers (16)
Phase 1 (12347)
Phase 2 (18590)
Phase 3 (15269)
Pipeline (3134)
Policy (126)
Postmarket research (1668)
Preclinical (3801)
Press Release (18)
Prostate cancer (180)
Psychedelics (26)
Radiopharmaceuticals (178)
Rare diseases (434)
Real estate (2869)
Recruiting (19)
Regulatory (15714)
Reports (18)
Research institute (1655)
Resumes & cover letters (50)
Rett syndrome (16)
RNA editing (5)
RSV (39)
Schizophrenia (114)
Series A (116)
Series B (94)
Service/supplier (2)
Sickle cell disease (45)
Special edition (6)
Spinal muscular atrophy (104)
Sponsored (16)
Startups (2134)
Stomach cancer (11)
Supply chain (60)
Tariffs (25)
The Weekly (14)
Vaccines (508)
Venture capital (28)
Weight loss (212)
Women's health (56)
Worklife (4)
Date
Today (82)
Last 7 days (321)
Last 30 days (1101)
Last 365 days (16231)
2026 (1748)
2025 (16467)
2024 (19845)
2023 (22736)
2022 (30684)
2021 (32985)
2020 (32192)
2019 (28412)
2018 (21810)
2017 (18905)
2016 (18111)
2015 (21194)
2014 (16023)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
Location
Africa (367)
Alabama (30)
Alaska (2)
Arizona (177)
Arkansas (10)
Asia (25506)
Australia (4031)
California (5609)
Canada (1922)
China (792)
Colorado (287)
Connecticut (290)
Delaware (250)
Europe (49924)
Florida (955)
Georgia (226)
Hawaii (1)
Idaho (35)
Illinois (582)
India (32)
Indiana (380)
Iowa (11)
Japan (320)
Kansas (91)
Kentucky (19)
Louisiana (18)
Maine (28)
Maryland (895)
Massachusetts (3773)
Michigan (153)
Minnesota (445)
Mississippi (5)
Missouri (80)
Montana (19)
Nebraska (21)
Nevada (65)
New Hampshire (73)
New Jersey (1940)
New Mexico (10)
New York (1579)
North Carolina (821)
North Dakota (4)
Northern California (2666)
Ohio (214)
Oklahoma (8)
Oregon (28)
Pennsylvania (1360)
Puerto Rico (12)
Rhode Island (35)
South America (523)
South Carolina (60)
Southern California (2253)
Tennessee (126)
Texas (1027)
United States (21785)
Utah (194)
Virginia (142)
Washington D.C. (52)
Washington State (387)
West Virginia (4)
Wisconsin (71)
Wyoming (1)
394,028 Results for "orasi medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
/C O R R E C T I O N -- Orasis Pharmaceuticals/
January 28, 2026
·
8 min read
Press Releases
ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUT
November 14, 2025
·
7 min read
Press Releases
Orasis Pharmaceuticals Strengthens Leadership Team with Key Hires to Support the Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%
October 15, 2024
·
4 min read
Press Releases
Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea
October 17, 2024
·
4 min read
Press Releases
Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%
October 8, 2024
·
5 min read
FDA
Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
October 18, 2023
·
7 min read
FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia
Orasis Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).
February 21, 2023
·
3 min read
Press Releases
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
February 4, 2026
·
2 min read
Press Releases
NEW DATA DEMONSTRATE QLOSI™ IS PUPIL SELECTIVE WITH CILIARY MUSCLE MOVEMENT NO DIFFERENT THAN A BALANCED SALT SOLUTION (BSS) CONTROL
January 28, 2026
·
7 min read
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).
January 3, 2023
·
3 min read
1 of 39,403
Next